Verrica Pharmaceuticals Inc
VRCA
查看详细走势图
6.910USD
+0.300+4.54%
收盘 02/06, 16:00（美东）报价延迟15分钟
65.58M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.54%
5天
-1.71%
1月
-14.16%
6月
+13.00%
今年开始到现在
-16.85%
1年
+1.07%
查看详细走势图
TradingKey Verrica Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Verrica Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名90/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.50。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Verrica Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Verrica Pharmaceuticals Inc亮点
亮点风险
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
业绩增长期
公司处于发展阶段，最新年度总收入7.57M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.57M美元
估值低估
公司最新PE估值-2.42，处于3年历史低位
机构减仓
最新机构持股3.04M股，环比减少13.99%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值29.19K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.95
分析师目标
根据
5
位分析师
买入
评级
16.500
目标均价
+149.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Verrica Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Verrica Pharmaceuticals Inc简介
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
公司代码VRCA
公司Verrica Pharmaceuticals Inc
CEORieger (Jayson)
网址https://verrica.com/
相关品种
